Phenotypic characterisation of pro-inflammatory monocytes and dendritic cells in peripheral arterial disease

Summary

Atherosclerosis is a chronic inflammatory process involving antigen-presenting cells like monocytes and dendritic cells (DC). The aim of this study was to perform a phenotypic characterisation of these cell types in patients with different degrees of peripheral arterial disease (PAD). Sixty patients with PAD [N= 30 intermittent claudication (IC), N= 30 critical limb ischemia (CLI)] and 30 controls were included. Peripheral blood leucocytes were analysed from peripheral blood by flow cytometry using different gating strategies to directly identify and analyse monocytes, myeloid DC, (mDC) and plasmacytoid DC (pDC). PAD patients showed a significantly higher proportion of proinflammatory CD14++CD16+ monocytes (p<0.0001) compared with healthy individuals. We found an increased number of mDC/ml and a reduced number of pDC/ml (both p<0.01) in PAD patients, leading to a shift in the mDC/pDC ratio (p<0.01). As compared to patients with intermittent claudication, CLI patients presented a reduced expression of HLA-DR (p<0.01), CD86 and CD40 on both mDCs and pDCs (p<0.01). Peripheral blood monocytes show a proinflammatory phenotype in PAD patients compared to controls. In contrast, CLI patients show a reduced expression of proinflammatory markers. We hypothesise that severe ischaemia and/or prolonged inflammation in CLI might lead to a paradoxical attenuation in the proinflammatory membrane pattern of circulating mononuclear cells, possibly hindering an adequate regulatory function of mDCs and pDCs and favouring the progression of disease.

Keywords

Monocytes - dendritic cells - inflammation - peripheral arterial disease

• References

• 1 Norgren L, Hiatt WR, Dormandy JA. et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33 (Suppl. 01) S1-75. (Suppl. 01)
• 2 Bhatt DL, Steg PG, Ohman EM. et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. J Am Med Assoc 2006; 295: 180-189.
• 3 Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115-126.
• 4 Hansson GK, Libby P, Schönbeck U. et al. Innate and Adaptive Immunity in the Pathogenesis of Atherosclerosis. Circ Res 2002; 91: 281-291.
• 5 Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011; 17: 1410-1422.
• 6 Ni K, O’Neill HC. The role of dendritic cells in T-cell activation. Immunol Cell Biol 1997; 75: 223-230.
• 7 Ziegler-Heitbrock L, Ancuta P, Crowe S. et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010; 116: e74-80.
• 8 Belge KU, Dayyani F, Horelt A. et al. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol 2002; 168: 3536-3542.
• 9 Schlitt A, Heine G, Blankenberg S. et al. CD14+CD16+ Monocytes are a Risk factor for Coronary Artery Disease and related to Serum TNF-a-levels. Thromb Haemost 2004; 92: 419-424.
• 10 Hristov M, Leyendecker T, Schuhmann C. et al. Circulating monocyte subsets and cardiovascular risk factors in coronary artery disease. Thromb Haemost 2010; 104: 412-414.
• 11 Bobryshev YV, Lord RSA. S-100 positive cells in human arterial intima and in atherosclerotic lesions. Cardiovasc Res 1995; 29: 689-696.
• 12 Yilmaz A, Lochno M, Traeg F. et al. Emergence of dendritic cells in rupture-prone regions of vulnerable carotid plaques. Atherosclerosis 2004; 176: 101-110.
• 13 Niessner A, Sato K, Chaikof EL. et al. Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-alpha. Circulation 2006; 114: 2482-2489.
• 14 Yilmaz A, Weber J, Cicha I. et al. Decrease in Circulating Myeloid Dendritic Cell Precursors in Coronary Artery Disease. J Am Coll Cardiol 2006; 48: 70-80.
• 15 Van Vre EA, Hoymans VY, Bult H. et al. Decreased number of circulating plasmacytoid dendritic cells in patients with atherosclerotic coronary artery disease. Coron Artery Dis 2006; 17: 243-248.
• 16 Shortman K, Naik SH. Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol 2007; 7: 19-30.
• 17 Shimada K. Immune system and atherosclerotic disease: heterogeneity of leukocyte subsets participating in the pathogenesis of atherosclerosis. Circ J 2009; 73: 994-1001.
• 18 Randolph GJ, Ochando J, Partida-Sanchez S. Migration of dendritic cell subsets and their precursors. Annu Rev Immunol 2008; 26: 293-316.
• 19 Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449: 419-426.
• 20 Matta BM, Castellaneta A, Thomson AW. Tolerogenic plasmacytoid DC. Eur J Immunol 2010; 40: 2667-2676.
• 21 Della Bella S, Giannelli S, Taddeo A. et al. Application of six-color flow cytometry for the assessment of dendritic cell responses in whole blood assays. J Immunol Methods 2008; 339: 153-164.
• 22 Borissoff JI, Spronk HM, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med 2011; 364: 1746-1760.
• 23 Langer HF, Daub K, Braun G. et al. Platelets recruit human dendritic cells via Mac-1/JAM-C interaction and modulate dendritic cell function in vitro. Arterioscler Thromb Vasc Biol 2007; 27: 1463-1470.
• 24 Bobryshev YV, Lord RSA. Ultrastructural recognition of cells with dendritic cell morphology in human aortic intima. Contacting interactions of Vascular Dendritic Cells in arthero-resistant and artheroprone areas of the normal aorta. Arch Histol Cytol 1995; 58: 307-322.
• 25 Millonig G, Niederegger H, Rabl W. et al. Network of Vascular-Associated Dendritic Cells in Intima of Healthy Young Individuals. Arterioscler Thromb Vasc Biol 2001; 21: 503-508.
• 26 Millonig G, Schwentner C, Mueller P. et al. The vascular-associated lymphoid tissue: a new site of local immunity. Curr Opin Lipidol 2001; 12: 547-553.
• 27 Belge KU, Dayyani F, Horelt A. et al. The Proinflammatory CD14+CD16+DR++ Monocytes Are a Major Source of TNF. J Immunol 2002; 168: 3536-3542.
• 28 Ziegler-Heitbrock HWL, Fingerle G, Ströbel M. et al. The novel subset of CD14+/CD16+ blood monocytes exhibits features of tissue macrophages. Eur J Immunol 1993; 23: 2053-2058.
• 29 Acunta P, Weiss L, Haeffner-Cavaillon N. CD14+CD16++ cells derived in vitro from peripheral blood monocytes exhibit phenotypic and functional dendritic cell-like characteristics. Eur J Immunol 2000; 30: 1872-1883.
• 30 Randolph GJ, Sanchez-Schmitz G, Liebman RM. et al. The CD16+ (Fc{gamma}RIII+) Subset of Human Monocytes Preferentially Becomes Migratory Dendritic Cells in a Model Tissue Setting. J Exp Med 2002; 196: 517-527.
• 31 Schakel K, Kannagi R, Kniep B. et al. 6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells. Immunity 2002; 17: 289-301.
• 32 de Baey A, Mende I, Riethmueller G. et al. Phenotype and function of human dendritic cells derived from M-DC8+ monocytes. Eur J Immunol 2001; 31: 1646-1655.
• 33 Ancuta P, Moses A, Gabuzda D. Transendothelial migration of CD16+ monocytes in response to fractalkine under constitutive and inflammatory conditions. Immunobiology 2004; 209: 11-20.
• 34 Ancuta P, Rao R, Moses A. et al. Fractalkine preferentially mediates arrest and migration of CD16+ monocytes. J Exp Med 2003; 197: 1701-1707.
• 35 Llodra J, Angeli V, Liu J. et al. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc Natl Acad Sci USA 2004; 101: 11779-11784.
• 36 Berg KE, Ljungcrantz I, Andersson L. et al. Elevated CD14++CD16- monocytes predict cardiovascular events. Circ Cardiovasc Genet 2012; 5: 122-131.
• 37 Hristov M, Leyendecker T, Schuhmann C. et al. Circulating monocyte subsets and cardiovascular risk factors in coronary artery disease. Thromb Haemost 2010; 104: 412-414.
• 38 Swirski FK, Libby P, Aikawa E. et al. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 2007; 117: 195-205.
• 39 Weber C, Belge KU, von Hundelshausen P. et al. Differential chemokine receptor expression and function in human monocyte subpopulations. J Leukoc Biol 2000; 67: 699-704.
• 40 Zawada AM, Rogacev KS, Rotter B. et al. SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset. Blood 2011; 118: e50-61.
• 41 Pucci F, Venneri MA, Biziato D. et al. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood „resident“monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood 2009; 114: 901-914.
• 42 Hristov M, Schmitz S, Schuhmann C. et al. An optimized flow cytometry protocol for analysis of angiogenic monocytes and endothelial progenitor cells in peripheral blood. Cytometry A 2009; 75: 848-853.
• 43 Girndt M, Köhler H, Schiedhelm Weick E. et al. T cell activation defect in hemodialysis patients: evidence for a role of the B7/CD28 pathway. Kidney Int 1993; 44: 359-365.
• 44 Girndt M, Sester U, Sester M. et al. Impaired cellular immune function in patients with end-stage renal failure. Nephrol Dial Transplant 1999; 14: 2807-2810.
• 45 Daissormont IT, Christ A, Temmerman L. et al. Plasmacytoid dendritic cells protect against atherosclerosis by tuning T-cell proliferation and activity. Circ Res 2011; 109: 1387-1395.
• 46 Doring Y, Manthey HD, Drechsler M. et al. Auto-antigenic protein-DNA complexes stimulate plasmacytoid dendritic cells to promote atherosclerosis. Circulation 2012; 125: 1673-1683.
• 47 Niessner A, Weyand CM. Dendritic cells in atherosclerotic disease. Clin Immunol 2010; 134: 25-32.
• 48 Dzionek A, Fuchs A, Schmidt P. et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 2000; 165: 6037-6046.
• 49 Rovati B, Mariucci S, Manzoni M. et al. Flow cytometric detection of circulating dendritic cells in healthy subjects. Eur J Histochem 2008; 52: 45-52.